



Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations

October 2, 2017

SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured its first [patent](#) covering the company's innovative Dropless Therapy® formulations from the Australian Patent office, a division of IP Australia. Patent 2014293665, "Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent" will expire March 27, 2034, not including any potential extensions.



Mark L. Baum, CEO of Imprimis, stated, "This composition patent granted by the Australian Patent Office covering our flagship Dropless Therapy® program is an important milestone and validation for our company, particularly in light of our ability to ship Dropless Therapy® formulations overseas from our FDA-registered outsourcing facility. We anticipate this will be the first of several patents to be issued for our Dropless Therapy®, LessDrops®, and other key ophthalmic products in the U.S. and abroad. Protecting these valuable assets is critical, and the issuance of this key patent not only strengthens our IP portfolio, but sets a strong precedent that our core technology is truly novel and innovative."

About Imprimis' Dropless Therapy

Imprimis' Dropless Therapy® compounded antibiotic and steroid formulations are available in single, injectable intraocular doses administered by physicians following ocular surgery. Dropless Therapy® may substantially reduce or eliminate the need for patient-administered eye drops following surgery, thereby potentially eliminating patient non-compliance and dosing errors associated with post-operative care regimens. Dropless Therapy® can simplify the post-operative care process, provide safeguards against bacterial infection and inflammation, and may decrease overall costs. These sterile ophthalmic compounded formulations use the company's SSP Technology®, which allows for active pharmaceutical ingredients that ordinarily do not mix well to solubilize into a predictable, well-distributed, micronized particle suspension. Dropless Therapy® formulations are optimized for isotonicity and pH most compatible for ophthalmic use. Every batch is tested for sterility prior to dispensing and a complimentary copy of the test report is included with each prescription. More information is available at <http://www.imprimisrx.com/formulations/ophthalmology/dropless/>.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states. The company's unique business model increases patient access and affordability to many critical medicines. Headquartered in San Diego, California, Imprimis owns and operates production and dispensing facilities located in California and New Jersey. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded

formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws.

Investor Contact

Jon Patton

jpatton@imprimispharma.com

858-704-4587